Onco Wiki / drapeau rouge

Current or prior tamoxifen exposure ≥5 years in a woman with intact uterus (no prior hyst...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-IATROGENIC-TAMOXIFEN-ENDOMETRIAL-PREVENTION
TypeSignal d’alerte
Étatreviewed 2026-05-18 | pending_clinical_signoff
MaladiesDIS-ENDOMETRIAL
SourcesSRC-NCCN-BREAST-2025 SRC-NCCN-UTERINE-2025

Origine du drapeau rouge

DéfinitionCurrent or prior tamoxifen exposure ≥5 years in a woman with intact uterus (no prior hysterectomy). Tamoxifen is a selective estrogen- receptor modulator (SERM) — antagonist in breast tissue (therapeutic for ER+ breast cancer + risk reduction) but partial agonist in endometrium → ~2-7 fold increased endometrial cancer risk (predominantly endometrioid; less commonly serous, carcinosarcoma). Cumulative risk ~1-2% over 5y treatment; higher with longer duration + post-menopausal status. Endometrial cancers in tamoxifen-exposed women often more aggressive histology than spontaneous. Population with hysterectomy: this RF does NOT fire (no at-risk organ). Patient with ER+ breast cancer (treatment-time persona) ALSO has prevention- persona considerations covered by this RF. Prevention-persona RedFlag (§20 v0.3 iatrogenic pilot).
Direction cliniqueenquêter
Catégorieautres

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "current_tamoxifen_use_ge_5y",
      "value": true
    },
    {
      "finding": "prior_tamoxifen_completion_intact_uterus",
      "value": true
    },
    {
      "finding": "tamoxifen_post_menopausal_intact_uterus",
      "value": true
    }
  ],
  "type": "lab_value"
}

Notes

Prevention-persona RedFlag for tamoxifen exposure ≥5y in women with intact uterus. ~2-7 fold endometrial cancer risk. Engine routes to PreventionPlan recommending symptom-prompted evaluation (postmenopausal bleeding → immediate workup with TVUS + endometrial biopsy). Routine asymptomatic TVUS screening NOT recommended per ACOG (false-positives from tamoxifen-related subepithelial changes). STUB pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode.

Utilisé par

Indication

Signal d’alerte